Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00QOF
|
|||
| Former ID |
DIB000806
|
|||
| Drug Name |
ORG-13011
|
|||
| Synonyms |
FIBOFLAPON; 936350-00-4; UNII-Y1NA96IX3T; Y1NA96IX3T; CHEMBL1922660; Fiboflapon [USAN:INN]; AM803; Fiboflapon (USAN); AM-803; AM 803; SCHEMBL11820; DTXSID20239496; DFQGDHBGRSTTHX-UHFFFAOYSA-N; GSK2190915B; ZINC68247071; BDBM50359080; AKOS030527019; SB16524; CS-3604; Fiboflapon; NCGC00485966-01; HY-15874; 1H-Indole-2-propanoic acid, 3-((1,1-dimethylethyl)thio)-1-((4-(6-ethoxy-3-pyridinyl)phenyl)methyl)-alpha,alpha-Dimethyl-5-((5-methyl-2-pyridinyl)methoxy)-; D10069
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Phase 2 | [1] | |
| Psychotic disorder [ICD-11: 6A20-6A25] | Phase 2 | [2] | ||
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Application submitted | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H25F3N4O
|
|||
| Canonical SMILES |
C1CC(=O)N(C1)CCCCN2CCN(CC2)C3=NC=CC(=C3)C(F)(F)F
|
|||
| InChI |
1S/C18H25F3N4O/c19-18(20,21)15-5-6-22-16(14-15)24-12-10-23(11-13-24)7-1-2-8-25-9-3-4-17(25)26/h5-6,14H,1-4,7-13H2
|
|||
| InChIKey |
YKJJCYZZWWSBEW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 142494-12-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Antagonist | [3], [4] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT00000189) Gepirone vs Placebo in Treatment of Cocaine Dependence - 3. U.S. National Institutes of Health. | |||
| REF 3 | Antagonism of the 5-HT1A receptor stimulus in a conditioned taste aversion procedure. Eur Neuropsychopharmacol. 1999 Jun;9(4):345-9. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.